Not provided
Not provided
Not provided
Not provided
Sponsor decision
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
After treatment for Hodgkin disease, secondary cancer, in particular breast cancer induced by treatment, are the first cause of death.
The investigators will estimate the risk to develop breast cancer in this population of women treated for hodgkin disease, and will propose women at high rish to participate in an intensive screening program based on an annual detection based on mammography, echography, and RMI.
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| intensive screening | Experimental | annual breast cancer detection based on mammography, echography and RMI. |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| intensive screening | Procedure | Each year, women will have breast cancer detection based on mammography, echography and RMI. Questionaries will also be completed. |
|
| Measure | Description | Time Frame |
|---|---|---|
| efficacy of the screening | The efficacy of the screening will be evaluated by the rate of early stage breast cancer detected. The rate of in situ, < 10 mm(T1b), and N0 will be estimated. | 15 years |
| Measure | Description | Time Frame |
|---|---|---|
| interest | The rate of interest is the % of women at high risk who will accept the intensive screening | 1 month |
| adhesion | The adhesion rate is the % of women who will effectively undergo the first screnning among the women who had accepted their participation in this intensive screening |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| François EISINGER, PhD | Institut Paoli-Calmettes | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| François EISINGER, PhD | Marseille | 13009 | France |
Not provided
| Label | URL |
|---|---|
| institut Paoli-Calmettes web site | View source |
Not provided
Not provided
| ID | Term |
|---|---|
| D006689 | Hodgkin Disease |
| D001943 | Breast Neoplasms |
| ID | Term |
|---|---|
| D008223 | Lymphoma |
| D009370 | Neoplasms by Histologic Type |
| D009369 | Neoplasms |
| D008232 | Lymphoproliferative Disorders |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| 1 month |
| compliance | The compliance will be evaluated yearly. The number of exam realised compared to the theoric number and the time between 2 exams will be estimated. | 15 years |
| psychologic impact | The psychologic impact will be assessed yearly by questionnaries evaluating quality of life, anxiety and satisfaction. | 15 years |
| D008206 |
| Lymphatic Diseases |
| D006425 | Hemic and Lymphatic Diseases |
| D007160 | Immunoproliferative Disorders |
| D007154 | Immune System Diseases |
| D009371 | Neoplasms by Site |
| D001941 | Breast Diseases |
| D012871 | Skin Diseases |
| D017437 | Skin and Connective Tissue Diseases |